Isis receives $3m investment
The company is developing IsisIQ, a patch that uses iontophoresis to deliver therapeutics across this skin. Iontophoresis uses a small electric charge to increase the permeability of the skin and allow the therapeutic molecule to enter the blood.
Isis believes its product, which consists of an electrode, hydrogel and selective barrier membrane, is capable of delivering a wide variety of drugs, and if necessary multiple therapeutics from a single patch.
The product is supported by software that helps healthcare professionals manage a patient’s administration regime. For example, each patch can be programmed to match a patient’s specific dosing requirements and the physician can continue to monitor and adjust the levels.
Adoption of the technology could increase compliance, avoid under or over dosing and ensure reliable cessation of drug delivery, according to Isis.
The company is also developing other transdermal products, including Gentle Touch which uses the technology underpinning IsisIQ to deliver lidocaine to numb the skin prior to self-injection.
Isis believes Gentle Touch could eliminate the pain and anxiety associated with self-injection. The product is designed specifically for children and elderly patients.
Isis has now been backed by 26 investors who have put a total of $3m into the company. Neither the names of the investors or how the funding will be used were detailed in the SEC filing.
